Venus Remedies Ltd (VENUSREM)

📊 Quarterly Results (₹ Cr)

Revenue peaked at ₹259 crore in Q4 FY2026 but declined to ₹179 crore in Q1 FY2027, indicating seasonality or demand fluctuations. Operating margins dropped from 21.9% to 15.3% over the same period, suggesting margin pressure despite stable profitability. Net profit and EPS followed a similar downward trend, although annual net profit remained healthy at ₹52.55 crore. The company's financials reflect a shift from short-term profitability to reinvestment mode, with management framing long-term growth through capacity expansion and global market penetration.

🔮 Management Outlook & What's Next

Management expressed a strategic focus on sustainable growth through R&D, digital transformation, and global market expansion, particularly in emerging regions. The Venus Industrial Park is positioned as a cornerstone of future scalability, with a target capacity of 100 Crore units/year by 2030. No specific near-term financial targets or revenue guidance were provided, but the emphasis on debt-free operations and reinvestment suggests a capital allocation strategy prioritizing long-term infrastructure over immediate returns.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet remains exceptionally strong, with equity and reserves growing steadily while borrowings remain negligible (₹12-14 crores). Total assets increased from ₹716 crore in FY2025 to ₹854 crore in FY2026, reflecting asset base expansion likely tied to operational investments. The debt-free status and rising reserves support a conservative capital allocation strategy, enabling flexibility for strategic investments, dividend continuity, and resilience against market volatility.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 41.76%, indicating confidence in long-term prospects. Institutional ownership (FII and DII) has shown gradual accumulation, rising from 1.86% (FII) and 0.75% (DII) in Q2FY26 to 2.92% (FII) and 0.89% (DII) in Q1FY27. The growing number of public shareholders (21,905 in Q1FY27) suggests increasing retail and institutional interest. No pledging activity is evident, and the shareholder base is broadening, which may support future liquidity and valuation.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) Revenue volatility and declining operating margins in recent quarters raise concerns about near-term growth sustainability. 2) Heavy reliance on international markets exposes the company to geopolitical, regulatory, and currency risks, particularly in emerging economies. 3) The success of the Venus Industrial Park and expansion into new regions depends on execution capability and capital efficiency, with no guaranteed timeline for returns. 4) Intensifying competition in the global generics and specialty pharmaceutical space could pressure pricing and market share.

📋 Recent Filings

• Announcement2026-09-25Venus Remedies announced that its insider trading window will close on September 25, 2026, following SEBI regulations, preventing designated persons a…
• share transfer2026-09-08Venus Remedies announced a special window for re-lodging transfer requests of physical shares via social media platforms Facebook, Instagram, and X, a…
• 🟡 Board Meeting2026-08-20Venus Remedies Limited announced board appointments and reappointments at its 37th Annual General Meeting on August 20, 2026, including Saransh Chaudh…
• 🟡 Board Meeting2026-08-20Venus Remedies held its 37th Annual General Meeting on 20th August 2026 via video conference, where shareholders approved the audited standalone and c…
• 🔴 annual report2026-07-24Venus Remedies Limited announced its 37th AGM on August 20, 2026, via video conferencing, with resolutions including adoption of new Articles of Assoc…
• Announcement2026-07-18Venus Remedies Limited issued a social media announcement urging shareholders to update their KYC details via links on Facebook, Instagram, LinkedIn, …
• Financial Results2026-06-25Venus Remedies Limited announced that its designated insiders must remain in a trading window closure from July 1, 2026, until 48 hours after the unau…
• Announcement2026-06-16Venus Remedies Limited issued a social media alert on June 16, 2026, directing shareholders to official links for updating KYC details, reinforcing co…
• Announcement2026-06-04Venus Remedies announced that its research unit Venus Medicine Research Centre has renewed its DSIR in-house R&D recognition from the Department of Sc…
• 🟡 Board Meeting2026-05-26Venus Remedies announced on May 26, 2026, that its board approved Q4 FY2026 financial results showing total income of **₹780.19 crores**, profit after…

🧠 Analyst's Read

Venus Remedies presents a stable yet evolving profile, anchored by strong profitability, a debt-free structure, and growing institutional interest, but near-term financial trends warrant monitoring. The company's strategic investments in infrastructure and global expansion offer long-term upside, though execution risks and margin pressures in core operations remain relevant. Investors should watch for updates on the Venus Industrial Park timeline, margin recovery signals, and management's ability to convert growth initiatives into sustainable earnings.

Based on filing content and financial data. Not a recommendation.